A Review on the Safety and Efficacy of Inhaled Corticosteroids in the Management of Asthma

被引：0
作者：
Ye Q. [1 ]
He X.-O. [2 ]
D’Urzo A. [3 ]
机构：
[1] John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI
[2] Faculty of Medicine, University of Manitoba, Winnipeg, MB
[3] Department of Family and Community Medicine, University of Toronto, Toronto, ON
来源：
Pulmonary Therapy | 2017年 / 3卷 / 1期
关键词：
Add on therapy; Airway inflammation; Asthma; Dose–response; Efficacy; Inhaled corticosteroids; Mechanism of action; Pathophysiology; Safety; Side effects;
D O I：
10.1007/s41030-017-0043-5
中图分类号：
学科分类号：
摘要：
Asthma is a chronic inflammatory disease characterized by symptoms of cough, dyspnea, chest tightness, and wheeze. Inhaled corticosteroids (ICS) have been recommended as initial therapy in the treatment of persistent asthma in all guidelines, as they have been shown to reduce morbidity and mortality. However, high-dose regimens and long-term use of ICS may be associated with a variety of side effects, similar to those observed with systemic corticosteroid therapy. These side effects include impaired growth in children, osteoporosis, fractures, glaucoma, cataracts, and skin thinning. The current recommendations on ICS use in asthma management will be reviewed in this article with a view to highlight treatment strategies that strike an optimal balance between safety and efficacy. © 2017, The Author(s).
引用
收藏
页码：1 / 18
页数：17
相关论文
共 165 条
  • [1] Myers T.R., Guidelines for asthma management: a review and comparison of 5 current guidelines, Respir Care, 53, 6, pp. 751-767, (2008)
  • [2] Ernst P., Spitzer W.O., Suissa S., Et al., Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use, JAMA., 268, pp. 3462-3464, (1992)
  • [3] Donahue J.G., Weiss S.T., Livingston J.M., Goetsch M.A., Greineder D.K., Platt R., Inhaled steroids and the risk of hospitalization for asthma, JAMA, 277, pp. 887-891, (1997)
  • [4] Suissa S., Ernst P., Benayoun S., Baltzan M., Cai B., Low-dose inhaled corticosteroids and the prevention of death from asthma, N Eng J Med., 343, 5, pp. 332-336, (2000)
  • [5] Rossi G.A., Cerasoli F., Cazzola M., Safety of inhaled corticosteroids: room for improvement, Pulm Pharmacol Ther, 20, pp. 23-25, (2007)
  • [6] Dahl R., Systemic side effects of inhaled corticosteroids in patients with asthma, Respir Med, 100, 8, pp. 1307-1317, (2006)
  • [7] Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma, (2007)
  • [8] Bell M.C., Busse W.W., The Biology of Asthma, Fishman’s Pulmonary Diseases and Disorders, (2015)
  • [9] Johansson A.K., Sergejeva S., Sjostrand M., Lee J.J., Lotvall J., Allergen-induced traffic of bone marrow eosinophils, neutrophils and lymphocytes to airways, Eur J Immunol, 34, pp. 3135-3145, (2004)
  • [10] Busse W.W., Lemanske R.F., Asthma, N Engl J Med, 344, 5, pp. 350-362, (2001)
12345678910